Stockscreener 앱 받기
77.72
7.12%
4.987
전일 마감가:
$72.73
열려 있는:
$73.62
하루 거래량:
2.80M
Relative Volume:
0.50
시가총액:
$29.98B
수익:
$4.82B
순이익/손실:
$930.40M
주가수익비율:
33.24
EPS:
2.3381
순현금흐름:
$1.43B
1주 성능:
+6.69%
1개월 성능:
+6.49%
6개월 성능:
+12.03%
1년 성능:
-7.40%
1일 변동 폭
$73.12
$79.15
1주일 범위
$72.08
$79.15
52주 변동 폭
$54.11
$89.98
덱스컴 Stock (DXCM) Company Profile
명칭
Dexcom Inc
전화
(858) 200-0200
주소
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
77.69 | 28.06B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
98.90 | 155.49B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.26 | 121.31B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.39 | 103.01B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
44.60 | 63.97B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.95 | 50.25B | 6.30B | 1.07B | 1.09B | 1.8406 |
덱스컴 Stock (DXCM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2026-01-12 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-12-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 개시 | Evercore ISI | In-line |
| 2025-10-21 | 재개 | Stifel | Buy |
| 2025-09-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-21 | 개시 | Argus | Buy |
| 2025-06-16 | 개시 | Truist | Buy |
| 2025-05-30 | 개시 | Goldman | Buy |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-03 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 개시 | Redburn Atlantic | Neutral |
| 2024-03-12 | 개시 | RBC Capital Mkts | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-04-17 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 개시 | UBS | Buy |
| 2023-01-26 | 개시 | Wolfe Research | Outperform |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-15 | 개시 | Bernstein | Outperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-01-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-28 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2021-01-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-10-02 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 재확인 | Piper Sandler | Overweight |
| 2020-05-14 | 개시 | Wells Fargo | Equal Weight |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-11-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-11-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-10-23 | 개시 | Stifel | Buy |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-19 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-09-12 | 업그레이드 | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 재확인 | Canaccord Genuity | Buy |
| 2018-07-02 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
| 2018-05-03 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-04 | 개시 | Goldman | Sell |
| 2018-04-04 | 개시 | Guggenheim | Neutral |
| 2018-03-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | 다운그레이드 | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 재확인 | Wedbush | Outperform |
모두보기
덱스컴 주식(DXCM)의 최신 뉴스
Truist Adjusts Price Target on DexCom to $87 From $80, Maintains Buy Rating - marketscreener.com
US252131AM9 Bond Profile — Key Metrics - TradingView
How Health Canada’s Longer-Wear CGM Approval At DexCom (DXCM) Has Changed Its Investment Story - simplywall.st
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
DXCM Company (NASDAQ: DXCM) shareholder to sell 1,700 shares - Stock Titan
DexCom Inc. stock outperforms competitors despite losses on the day - MarketWatch
DXCM Secures Health Canada Authorization for Dexcom G7 15 Day CGM - The Globe and Mail
Dexcom G7 15 Day CGM System Receives Health Canada Approval - Medical Product Outsourcing
Dexcom receives Health Canada authorization for G7 15 Day CGM By Investing.com - Investing.com South Africa
Global Blood Glucose Monitoring System Market Size to Reach USD 39.4 Billion by 2035 | Growing at 8.9% CAGR | Industry Trends, Market Share & Forecast – Custom Market Insights - GlobeNewswire Inc.
Dexcom (DXCM) Gains Health Canada Approval for New CGM System - GuruFocus
Dexcom receives Health Canada authorization for G7 15 Day CGM - Investing.com
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
DEXCOM,-INC. - The Facts
Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes - Dexcom Investor Relations
Here's why you should retain DexCom stock in your portfolio - MSN
Dexcom stock holds steady on its glucose monitor business - Ad Hoc News
JPMorgan (NYSE: JPM) sells $2.01M DexCom-linked auto callable contingent interest notes - Stock Titan
DEXCOM INC (NASDAQ:DXCM) Screens as a Strong Growth Stock with Favorable Technical Setup - ChartMill
Is DexCom (DXCM) Undervalued Following Its Investor Day Sentiment Shift? - Yahoo Finance
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - AOL.com
DexCom Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Dexcom to release Q2 2026 earnings on July 30, 2026 - scanx.trade
Is DexCom’s (DXCM) Sensor Recall Exposing Deeper Questions About Its Quality Controls and Data Systems? - Sahm
Investors’ Confidence in DexCom (DXCM) Rises as Growth Outlook Reassured - Yahoo Finance
Press Release: Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 P.m. Eastern Time - Moomoo
Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time - Business Wire
Dexcom Inc. focuses on continuous glucose monitoring as investors track long-term growth - AD HOC NEWS
Dexcom Inc. focuses on continuous glucose monitoring growth. Long-term diabetes trends support the b - Ad-hoc-news.de
Dexcom (DXCM) Executive Chair sells 26,756 shares in 10b5-1 open-market trade - Stock Titan
Dexcom Inc. updates its diabetes tech platform as investors track long-term growth - AD HOC NEWS
Devon Energy Corp focuses on U.S. shale production as investors track cash returns - AD HOC NEWS
DexCom (NASDAQ: DXCM) Form 144 lists proposed sale of 26,756 shares - Stock Titan
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now - Barchart
DXCMDexcom Inc Latest SEC Filings - Finviz
Earnings Preview: What To Expect From DexCom's Report - Yahoo Finance
Dexcom G7 Continuous Glucose Monitor from Dexcom Inc.smaller sensor and direct-to-watch in the US - AD HOC NEWS
JPMorgan (NYSE: JPM) offers autocall contingent-interest notes tied to DexCom stock - Stock Titan
DexCom shareholders urged to act as law firm pr... - Pluang
Patient Monitoring Stocks Q1 Results: Benchmarking DexCom (NASDAQ:DXCM) - Yahoo Finance
Securities Fraud Class Action Filed Against DexCom, Inc. (DXCM) – - The National Law Review
DXCM News | DEXCOM INC (NASDAQ:DXCM) - ChartMill
DexCom Inc (DXCM) Stock Up 3.5% and Still Undervalued -- GF Scor - GuruFocus
DexCom Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
DexCom: The Growth Thesis Still Needs To Be Proven - Seeking Alpha
Dexcom G7 CGM sensoraccessory that makes stacking multiple days easier - AD HOC NEWS
Enterprise value to revenue forward of DexCom, Inc. – NASDAQ:DXCM - TradingView
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating DexCom, Inc. (DXCM) And Encourages Investors to Connect - The National Law Review
Devon Energy Wolfcamp development programshale wells drive long-term output - AD HOC NEWS
Is DexCom Inc (DXCM) a Bargain After 3.8% Drop? GF Value Says Un - GuruFocus
덱스컴 (DXCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
덱스컴 주식 (DXCM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| SAYER KEVIN R | Executive Chair |
Jul 06 '26 |
Sale |
72.00 |
26,756 |
1,926,432 |
355,726 |
1.12%
0.22%
자본화:
|
볼륨(24시간):